3 assets in Epithelioid Hemangioendothelioma

Therapeutic assets addressing Epithelioid Hemangioendothelioma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Benzenesulfonamide, N-Methyl-3-(1-Methyl-1H-Imidazol-4-Yl)-4-[[[4-(Trifluoromethyl)Phenyl]Methyl]Amino]- Epithelioid Hemangioendothelioma	Ikena Oncology	P1	CC (43)
Osimertinib Epithelioid Hemangioendothelioma	Ikena Oncology	P1	CC (43)
bgc515 Epithelioid Hemangioendothelioma	BridGene Biosciences Inc.	P1	NR ()